{"organizations": [], "uuid": "c69a30c470e8489be75a903fb9c5a080e8e8066a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-novo-nordisk-ceo-new-ozempic-drug/brief-novo-nordisk-ceo-new-ozempic-drug-to-reach-at-least-dkk-1-billion-sales-in-2018-idUSC7N1JW02A", "country": "US", "domain_rank": 408, "title": "BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T09:46:00.000+03:00", "replies_count": 0, "uuid": "c69a30c470e8489be75a903fb9c5a080e8e8066a"}, "author": "", "url": "https://www.reuters.com/article/brief-novo-nordisk-ceo-new-ozempic-drug/brief-novo-nordisk-ceo-new-ozempic-drug-to-reach-at-least-dkk-1-billion-sales-in-2018-idUSC7N1JW02A", "ord_in_thread": 0, "title": "BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018", "locations": [], "entities": {"persons": [{"name": "eli lilly", "sentiment": "none"}, {"name": "stine jacobsen", "sentiment": "none"}, {"name": "lars fruergaard jorgensen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-novo nordisk", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 6:48 AM / in 11 minutes BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018 Reuters Staff 1 Min Read\nMay 2 (Reuters) - NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:\n* SALES OF OZEMPIC DIABETES DRUG IS EXPECTED TO REACH AT LEAST DKK 1 BILLION IN 2018\n* VICTOZA DIABETES DRUG STILL LOSING MARKET SHARE TO ELI LILLYâ€™S TRULICITY, ALBEIT AT LOWER PACE FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)", "external_links": [], "published": "2018-05-02T09:46:00.000+03:00", "crawled": "2018-05-02T10:06:53.000+03:00", "highlightTitle": ""}